The headline on the news article on the trial of omega-3 fatty acids in the
April 6 issue was strikingly misleading. While the open-label trial found"
some improvement in manic symptoms in children with bipolar
illness," the headline proclaimed, "Latest Hope for Omega-3 Fatty
Acids Shot Down for Child Bipolar Illness."
I'd say the quoted finding of a 30 percent reduction in the Young Mania
Rating Scale scores in half the subjects is quite hopeful. The concern about"
nonspecific study effects" is a concern in all research and
shouldn't lead us to reject such a safe, sensible approach to a very difficult